Conclusion: Current plasma octreotide values are significantly lower than previously reported for 30-, 60-, and 120-mg/mo LAR doses. Serial plasma octreotide value measurements should be used to determine if increasing symptoms or tumor growth are associated with suboptimal drug dosing.
- Improving Worldwide Cancer Care and Prevention Awareness
Oncology by PracticeUpdate
PracticeUpdate’s mission is to connect healthcare professionals with news and information that matters most for patient care. The site is tailored to deliver the latest expert curated content based on the clinician’s area of practice, and is optimized for viewing on any device. Individual access to PracticeUpdate is free, based upon users registering with the site.
TIP: for example, type “neuroendocrine tumors” (or other cancers) in the search window and you will receive a comprehensive list of up-to-date peer-review articles of neuroendocrine tumors from cancer-related journals, including The Lancet Oncology, New England Journal of Medicine, Journal of Clinical Oncology, etc. Many articles are full text.